Improvement in hypercalcemia with cinacalcet after kidney transplantation.

Titte R. Srinivas, Jesse D. Schold, Karl L. Womer, Bruce Kaplan, Richard J. Howard, Charles M. Bucci, Herwig Ulf Meier-Kriesche

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Cinacalcet, a calcimimetic, was evaluated in persistent hyperparathyroidism after kidney transplantation (Tx). Ten kidney transplant recipients and one kidney-pancreas recipient with persistent post-Tx hypercalcemia (serum calcium [SCa] > 10.2 mg/dl), stable graft function, and intact parathyroid hormone (iPTH) > or = 2 times normal received 30 mg/d cinacalcet between 2 mo and 5 yr after Tx. SCa, serum phosphorus (SP), and iPTH were measured before and after cinacalcet. Mean pre-cinacalcet SCa was 10.9 mg/dl (8.6 to 11.9 mg/dl). Average pre-cinacalcet SP was 2.9 mg/dl (1.8 to 4.0 mg/dl). Mean pre-cinacalcet iPTH was 267.0 pg/ml (99 to 723 pg/ml). After cinacalcet, SCa decreased on average by 1.6 mg/dl (95% confidence interval 1.2 to 2.1; P <0.0001). Post-cinacalcet SP increased on average 0.45 mg/dl (P = 0.046). Post-cinacalcet iPTH averaged 156.9 mg/dl (P = 0.10). Graft function remained stable. Cinacalcet lowers SCa and raises SP in the short term in patients with persistent post-Tx hyperparathyroidism; long-term bone effects and persistent hyperparathyroidism merit further study.

Original languageEnglish (US)
Pages (from-to)323-326
Number of pages4
JournalClinical Journal of the American Society of Nephrology
Volume1
Issue number2
DOIs
StatePublished - Mar 2006
Externally publishedYes

Fingerprint

Hypercalcemia
Kidney Transplantation
Serum
Parathyroid Hormone
Phosphorus
Hyperparathyroidism
Calcium
Cinacalcet Hydrochloride
Transplants
Kidney
Pancreas
Confidence Intervals
Bone and Bones

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Srinivas, T. R., Schold, J. D., Womer, K. L., Kaplan, B., Howard, R. J., Bucci, C. M., & Meier-Kriesche, H. U. (2006). Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clinical Journal of the American Society of Nephrology, 1(2), 323-326. https://doi.org/10.2215/CJN.00500705

Improvement in hypercalcemia with cinacalcet after kidney transplantation. / Srinivas, Titte R.; Schold, Jesse D.; Womer, Karl L.; Kaplan, Bruce; Howard, Richard J.; Bucci, Charles M.; Meier-Kriesche, Herwig Ulf.

In: Clinical Journal of the American Society of Nephrology, Vol. 1, No. 2, 03.2006, p. 323-326.

Research output: Contribution to journalArticle

Srinivas, TR, Schold, JD, Womer, KL, Kaplan, B, Howard, RJ, Bucci, CM & Meier-Kriesche, HU 2006, 'Improvement in hypercalcemia with cinacalcet after kidney transplantation.', Clinical Journal of the American Society of Nephrology, vol. 1, no. 2, pp. 323-326. https://doi.org/10.2215/CJN.00500705
Srinivas, Titte R. ; Schold, Jesse D. ; Womer, Karl L. ; Kaplan, Bruce ; Howard, Richard J. ; Bucci, Charles M. ; Meier-Kriesche, Herwig Ulf. / Improvement in hypercalcemia with cinacalcet after kidney transplantation. In: Clinical Journal of the American Society of Nephrology. 2006 ; Vol. 1, No. 2. pp. 323-326.
@article{18a57786eb474115883d7714232efc4d,
title = "Improvement in hypercalcemia with cinacalcet after kidney transplantation.",
abstract = "Cinacalcet, a calcimimetic, was evaluated in persistent hyperparathyroidism after kidney transplantation (Tx). Ten kidney transplant recipients and one kidney-pancreas recipient with persistent post-Tx hypercalcemia (serum calcium [SCa] > 10.2 mg/dl), stable graft function, and intact parathyroid hormone (iPTH) > or = 2 times normal received 30 mg/d cinacalcet between 2 mo and 5 yr after Tx. SCa, serum phosphorus (SP), and iPTH were measured before and after cinacalcet. Mean pre-cinacalcet SCa was 10.9 mg/dl (8.6 to 11.9 mg/dl). Average pre-cinacalcet SP was 2.9 mg/dl (1.8 to 4.0 mg/dl). Mean pre-cinacalcet iPTH was 267.0 pg/ml (99 to 723 pg/ml). After cinacalcet, SCa decreased on average by 1.6 mg/dl (95{\%} confidence interval 1.2 to 2.1; P <0.0001). Post-cinacalcet SP increased on average 0.45 mg/dl (P = 0.046). Post-cinacalcet iPTH averaged 156.9 mg/dl (P = 0.10). Graft function remained stable. Cinacalcet lowers SCa and raises SP in the short term in patients with persistent post-Tx hyperparathyroidism; long-term bone effects and persistent hyperparathyroidism merit further study.",
author = "Srinivas, {Titte R.} and Schold, {Jesse D.} and Womer, {Karl L.} and Bruce Kaplan and Howard, {Richard J.} and Bucci, {Charles M.} and Meier-Kriesche, {Herwig Ulf}",
year = "2006",
month = "3",
doi = "10.2215/CJN.00500705",
language = "English (US)",
volume = "1",
pages = "323--326",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "2",

}

TY - JOUR

T1 - Improvement in hypercalcemia with cinacalcet after kidney transplantation.

AU - Srinivas, Titte R.

AU - Schold, Jesse D.

AU - Womer, Karl L.

AU - Kaplan, Bruce

AU - Howard, Richard J.

AU - Bucci, Charles M.

AU - Meier-Kriesche, Herwig Ulf

PY - 2006/3

Y1 - 2006/3

N2 - Cinacalcet, a calcimimetic, was evaluated in persistent hyperparathyroidism after kidney transplantation (Tx). Ten kidney transplant recipients and one kidney-pancreas recipient with persistent post-Tx hypercalcemia (serum calcium [SCa] > 10.2 mg/dl), stable graft function, and intact parathyroid hormone (iPTH) > or = 2 times normal received 30 mg/d cinacalcet between 2 mo and 5 yr after Tx. SCa, serum phosphorus (SP), and iPTH were measured before and after cinacalcet. Mean pre-cinacalcet SCa was 10.9 mg/dl (8.6 to 11.9 mg/dl). Average pre-cinacalcet SP was 2.9 mg/dl (1.8 to 4.0 mg/dl). Mean pre-cinacalcet iPTH was 267.0 pg/ml (99 to 723 pg/ml). After cinacalcet, SCa decreased on average by 1.6 mg/dl (95% confidence interval 1.2 to 2.1; P <0.0001). Post-cinacalcet SP increased on average 0.45 mg/dl (P = 0.046). Post-cinacalcet iPTH averaged 156.9 mg/dl (P = 0.10). Graft function remained stable. Cinacalcet lowers SCa and raises SP in the short term in patients with persistent post-Tx hyperparathyroidism; long-term bone effects and persistent hyperparathyroidism merit further study.

AB - Cinacalcet, a calcimimetic, was evaluated in persistent hyperparathyroidism after kidney transplantation (Tx). Ten kidney transplant recipients and one kidney-pancreas recipient with persistent post-Tx hypercalcemia (serum calcium [SCa] > 10.2 mg/dl), stable graft function, and intact parathyroid hormone (iPTH) > or = 2 times normal received 30 mg/d cinacalcet between 2 mo and 5 yr after Tx. SCa, serum phosphorus (SP), and iPTH were measured before and after cinacalcet. Mean pre-cinacalcet SCa was 10.9 mg/dl (8.6 to 11.9 mg/dl). Average pre-cinacalcet SP was 2.9 mg/dl (1.8 to 4.0 mg/dl). Mean pre-cinacalcet iPTH was 267.0 pg/ml (99 to 723 pg/ml). After cinacalcet, SCa decreased on average by 1.6 mg/dl (95% confidence interval 1.2 to 2.1; P <0.0001). Post-cinacalcet SP increased on average 0.45 mg/dl (P = 0.046). Post-cinacalcet iPTH averaged 156.9 mg/dl (P = 0.10). Graft function remained stable. Cinacalcet lowers SCa and raises SP in the short term in patients with persistent post-Tx hyperparathyroidism; long-term bone effects and persistent hyperparathyroidism merit further study.

UR - http://www.scopus.com/inward/record.url?scp=33745607742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745607742&partnerID=8YFLogxK

U2 - 10.2215/CJN.00500705

DO - 10.2215/CJN.00500705

M3 - Article

C2 - 17699223

AN - SCOPUS:33745607742

VL - 1

SP - 323

EP - 326

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 2

ER -